47 episodes

Lupus Science and Medicine is a global, peer-reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Lupus Science and Medicine Podcast BMJ Podcasts

    • Health & Fitness

Lupus Science and Medicine is a global, peer-reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

    To RNase or Not to RNase: That Is the Question

    To RNase or Not to RNase: That Is the Question

    Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity.
     
    Read the related paper in LSM - https://doi.org/10.1136/lupus-2023-001113

    • 14 min
    A decision-aid facilitates patient understanding of benefits vs. risk of hydroxychloriquine use as part of routine care for lupus

    A decision-aid facilitates patient understanding of benefits vs. risk of hydroxychloriquine use as part of routine care for lupus

    Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare providers regarding the utilization of hydroxychloroquine, a cornerstone therapy in lupus. The tool can be accessed through the following link: http://hcqsafe.medicine.wisc.edu/
     
    Read the article: https://doi.org/10.1136/lupus-2023-000935

    • 15 min
    Dual dsDNA testing may be needed to fully understand patient disease status

    Dual dsDNA testing may be needed to fully understand patient disease status

    Dr. Anna Wolska speaks to Dr. Michael Belmont and Devyn Zaminski to discuss the importance of dual dsDNA testing in order to full understand disease activity. In this study, they made the observation that there is a large amount of discordance in anti-dsDNA antibodies assays. Misinterpretation or errors in anti- dsDNA antibody testing could have negative implications on long term outcomes in people living with SLE.
     
    Read the related paper - https://doi.org/10.1136/lupus-2023-001012

    • 21 min
    Is Anifrolumab an effective treatment for lupus nephritis?

    Is Anifrolumab an effective treatment for lupus nephritis?

    Dr. Anna Wolska engages in a discussion with renowned experts, Dr. Catharina Lindholm and Dr. David Jayne, to explore findings from the phase II TULIP Lupus Nephritis trial. This in-depth conversation centers on results from a clinical trial where they evaluated the efficacy of intensified anifrolumab treatment in individuals with active lupus nephritis.
     
    Read the article: http://dx.doi.org/10.1136/lupus-2023-000910

    • 12 min
    Which one is better at controlling lupus: Belimumab or Anifrolumab?

    Which one is better at controlling lupus: Belimumab or Anifrolumab?

    Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
     
    Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907

    • 12 min
    Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis

    Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis

    Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure.
     
    Read the related article - http://dx.doi.org/10.1136/lupus-2023-000932

    • 23 min

Top Podcasts In Health & Fitness

The Mind Full Podcast
Dermot Whelan
Passion Struck with John R. Miles
John R. Miles
Huberman Lab
Scicomm Media
Feel Better, Live More with Dr Rangan Chatterjee
Dr Rangan Chatterjee: GP & Author
Therapy Works
Julia Samuel
The Good Glow
The Good Glow Productions

You Might Also Like

Lupus: The Expert Series
Lupus Foundation of America
Lupus Speaks Podcast
Shedrica Holmes
LupusCorner Radio: Lupus Podcast
LupusCorner
The Lupus Academy
The Lupus Academy
JAMA Clinical Reviews
JAMA Network
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast